Originally posted at http://reuters.com
December 03, 2012

(Reuters) – Merck & Co Inc has moved to the forefront of Alzheimer’s disease research by starting a mid-stage study of a drug from a new class of oral medicines that aim to shut down production of a protein associated with the memory-robbing disease.

The drugmaker said on Monday it had started the trial to evaluate the safety and effectiveness of its so-called BACE inhibitor, named MK-8931, in patients with mild-to-moderate Alzheimer’s disease.

Read the full article at http://reuters.com.